Orchid's PDE-4 inhibitor shows early promise in European study
This article was originally published in Scrip
Orchid Chemicals & Pharmaceuticals expects to start Phase IIa studies in Europe by March with its oral phosphodiesterase-4 (PDE-4) inhibitor OCID 2987 for inflammatory disorders including chronic obstructive pulmonary disease (COPD), following promising early clinical results from a trial in the Netherlands.
You may also be interested in...
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
India has prohibited exports of hydroxychloroquine, though with concessions in specific instances, days after a national task force recommended the drug for the prophylaxis of SARS-CoV-2 infections. Home market supplies of the drug also appear strained for now.
Alembic says it is 'comfortably placed' in terms of inventories and is seeing improving API supplies from China. The only area of some concern is outbound logistics against a backdrop of flights being halted and population lock-downs.